A Study to Evaluate SHR-1210 in Subjects With Advanced HCC

PHASE2CompletedINTERVENTIONAL
Enrollment

220

Participants

Timeline

Start Date

November 15, 2016

Primary Completion Date

March 3, 2020

Study Completion Date

March 3, 2020

Conditions
Hepatocellular Carcinoma Non-Resectable
Interventions
BIOLOGICAL

SHR-1210

SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody

Trial Locations (17)

100021

Cancer Hospital Chinese Academy of Medical Science, Beijing

130012

Jilin Cancer Hospital, Changchun

150040

Haerbin Medical University Cancer Hospital, Haerbin

200032

Zhangshan Hospital Fudan University, Shanghai

Fudan University Shanghai Cancer Center, Shanghai

210002

81 Hospital Nanjing, Nanjing

230601

The Second Hospital of Anhui Medical University, Hefei

233004

The First Affiliated Hospital of Bengbu Medical College, Bengbu

310003

The First Affiliated Hospital Zhejiang University, Hangzhou

330006

The First Affiliated Hospital of Nanchang University, Nanchang

350001

Fujian Medical University Union Hospital, Fuzhou

410008

Xiangya Hospital Central South University, Changsha

410013

Hunan Cancer Hospital, Changsha

510080

Guangdong General Hospital, Guangzhou

515041

Cancer Hospital of Shantou University Medical College, Shantou

610041

West China Hospital, Chengdu

710061

The First Affiliated Hospital of Xi'an Jiaotong University, Xi’an

All Listed Sponsors
lead

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY

NCT02989922 - A Study to Evaluate SHR-1210 in Subjects With Advanced HCC | Biotech Hunter | Biotech Hunter